Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ACTRN12626001187336) titled 'A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose (SAD)/Multiple Ascending Dose (MAD) Safety, Pharmacokinetics and Immunogenicity Study of Nebulized IN-007 in Healthy Volunteers' on Sept. 24.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Inhalon Biopharma, Inc.
Condition:
Covid-19
Covid-19
Infection - Other infectious diseases
Respiratory - Other respiratory disorders / diseases
Intervention:
The study drug IN-007 is provided as an aqueous solution for nebulization. Participants will inhale the study drug ...